Lotte Biologics said on the 6th that it signed a contract for a contract development and manufacturing organization (CDMO) order for an anticancer drug candidate with a Japan-based global pharmaceutical company.
The company said it plans to actively pursue the establishment of a strategic cooperation system for the development and production of biopharmaceuticals through this contract. It decided not to disclose the counterparty and details under the terms of the agreement.
Lotte Biologics characterized this contract as the first collaboration between the two companies based on mutual trust. A company official said, "Based on this contract, we plan to accelerate efforts to strengthen competitiveness in global markets, including Japan."
※ This article has been translated by AI. Share your feedback here.